The use of the antiviral regimen Tenofovir
(TDF) based (Tenofovir/Lamivudine/Efavirenz) for the treatment of HIV has been
linked to dyslipidaemia, which is linked to cardiovascular problems and a
shorter life span. The study assessed the impact of Moringa oleifera
supplementation on metabolic anomalies related to HIV patients on TDF-based
regimen using a randomised comparative experiment. The RCT was a trial with two
arms that depended on time (intervention TDF-M and control TDF-NM). Out of the
140 individuals that were recruited, 56 were in the TDF-M group (received the
Moringa Supplement) and 84 were in the TDF-NM group (control). At baseline,
while at lower levels, more than 50% of the patients had abnormal atherogenic
lipoprotein indices (Log [TC/HDL-C] = 85.7%; TC/HDL-C = 58.5%; and LDL-C/HDL-C
= 51.4%). The proportion of TDF-M individuals at CVD risk has decreased. Following
the administration of the Moringa supplement for 12 weeks, the proportion of
TDF-NM subjects at risk for CVD increased to 53.6% (x2=26.67, P 0.001), a
significant (40.4 percent) drop. Higher TGL and LDL levels were seen in
CVD-at-risk HIV patients on a TDF-based regimen, which had an opposite effect
on HDL levels and a detrimental effect on atherogenic indices. After 4 weeks
(visit 1), the proportion changes between the TDF-M group and the TDF-NM group
were not statistically different; however, after 12 weeks (visit 2) of moringa
administration, the subjects on moringa had 4.67 [2.39 - 9.13] higher odds of
normal API (x2[Yates]=24.688; P0.001), 2.39 [1.58 - 3.60] higher odds of normal
TC/HDL-c (x2[Yates]= (P = 0.001; x2[Yates]=23.388). The atherogenic lipoprotein
indices of both groups saw significant changes during the research, with the
TDF-NM group showing improved values. This supports the argument for using
moringa as a dietary supplement to treat dyslipidemia brought on by ART.
Author(s) Details:
C. F. Anyanwu,
Department of
Pharmacology, University of Port Harcourt, Rivers State, Nigeria.
G. C. Owhonda,
Directorate of Public Health & Disease Control Services, Rivers State
Ministry of Health, Nigeria.
A. W. Obianime,
Department of Pharmacology, University of Port Harcourt, Rivers State,
Nigeria.
I. M. Siminialayi,
Department of Pharmacology, University of Port Harcourt, Rivers State,
Nigeria.
R. B. Kanee,
Institute of
Geoscience and Space Technology, Rivers State University, Port Harcourt,
Nigeria.
E. O. Aigbogun Jr.,
Department
of Anatomy, Faculty of Basic Medical Sciences, ESUT College of Medicine, Park
Ln Hospital Rd, GRA 400102, Enugu, Nigeria.
Please see the link here: https://stm.bookpi.org/CAPR-V5/article/view/7769
No comments:
Post a Comment